A novel approach to assess insulin sensitivity reveals no increased insulin sensitivity in mice with a dominant-negative mutant hepatocyte nuclear factor-1α

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 291, Issue 1, 2006, Pages

  Ahren B ^a   Pacini, G ^b  

^a LUND UNIVERSITY   (Sweden)

^b CNR   (Italy)

Author keywords

Diazoxide; Glucose effectiveness; Glucose tolerance; Insulin action; Minimal modeling

Indexed keywords

DIAZOXIDE; GLUCOSE; INSULIN; NUCLEAR FACTOR I;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; MEDICAL RESEARCH; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BLOOD GLUCOSE; DIAZOXIDE; FEMALE; GENE EXPRESSION REGULATION; GENES, DOMINANT; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MICE; MICE, INBRED C57BL; MUTATION;

EID: 33745726557     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00519.2005     Document Type: Article

References (30)

1. Ahrén B and Pacini G. Insufficient islet compensation to insulin resistance vs. reduced glucose effectiveness in glucose-intolerant mice. Am J Physiol Endocrinol Metab 283: E738-E744, 2002.
2. Ahrén B and Pacini G. Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Eur J Endocrinol 150: 97-104, 2004.
3. Ahrén B and Thorsson O. Increased insulin sensitivity is associated with reduced insulin and glucagon secretion and increased insulin clearance in man. J Clin Endocrinol Metab 88: 1264-1270, 2003.
4. Deems RO, Evans JL, Deacon RW, Honer CM, Chu DT, Bürki K, Fillers WS, and Cohen DK. Expression of human GLUT4 in mice results in increased insulin action. Diabetologia 37: 1097-1104, 1994.
5. Duckworth WC, Bennett ERG, and Hamel FG. Insulin degradation: progress and potential. Endocr Rev 19: 608-624, 1998.
6. Filipsson K, Pacini G, Scheurink AJW, and Ahrén B. PACAP stimulates insulin secretion but inhibits insulin sensitivity in mice. Am J Physiol Endocrinol Metab 274: E834-E842, 1998.
7. Goodarzi MO, Taylor KD, Guo X, Quinones MJ, Cui J, Li X, Hang T, Yang H, Holmes E, Hsueh WA, Olefsky J, and Rotter JI. Variation in the gene for muscle-specific AMP deaminase is associated with insulin clearance, a highly heritable trait. Diabetes 54:1222-1227, 2005.
8. Gupta RK, Vatamaniauk MZ, Lee CS, Flaschen RC, Fulmer JT, Matschinsky FM, Duncan SA, and Kaestner KH. The MODY1 gene HNF-4α regulates selected genes involved in insulin secretion. J Clin Invest 115: 1006-1015, 2005.
9. Hagenfeldt Johansson KA, Herrera PL, Wang H, Gjinovci A, Ishihara H, and Wollheim CB. β-cell-targeted expression of a dominant-negative hepatocyte nuclear factor-1α induces a maturity-onset diabetes of the young (MODY)3-like phenotype in transgenic mice. Endocrinology 142: 5311-5320, 2001.
10. Hansen JB, Arkhammar PO, Bödvarsdóttir TB, and Wahl P. Inhibition of insulin secretion as a new drug target in the treatment of metabolic disorders. Curr Med Chem 11: 1595-1615, 2004.
11. Härndahl L, Wierup M, Enerbäck S, Mulder H, Manganiello VC, Sundler F, Degerman E, Ahrén B, and Stenson Holst L. β-Cell targeted overexpression of phosphodiesterase 3B in mice causes impaired insulin secretion, glucose intolerance and deranged islet morphology. J Biol Chem 279: 15214-15222, 2004.
12. Hattersley AT. Maturity-onset diabetes of the young: clinical heterogeneity explained by genetic heterogeneity. Diabet Med 15: 15-24, 1998.
13. Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49: 1751-1760, 2000.
14. + fluxes and membrane potential in pancreatic B cells. Biochem Pharmacol 31: 1407-1415, 1982.
15. Heptulla RA, Stewart A, Enocksson S, Rife F, Ma TY, Sherwin RS, Tamboriane WV, and Caprio S. In situ evidence that peripheral insulin resistance in adolescents with poorly controlled type 1 diabetes is associated with impaired suppression of lipolysis: a microdialysis study. Pediatr Res 53: 830-835, 2003.
16. Karam JH, Grodsky GM, and Forsham PH. Excessive insulin response to glucose in obese subjects as measured by immunochemical assay. Diabetes 12: 197-294, 1963.
17. Larsson H and Ahrén B. Insulin resistant subjects lack islet adaptation to acute dexamethasone-induced reduction in insulin sensitivity. Diabetologia 42: 936-943, 1999.
18. Lautt WW, Wang X, Sadri P, Legare DI, and Macedo MP. Rapid insulin sensitivity test (RIST). Can J Physiol Pharmacol 76: 1080-1086, 1998.
19. Nijs HG, Radder JK, Frolich M, and Krans HM. In vivo relationship between insulin clearance and action in healthy subjects and IDDM patients. Diabetes 39: 333-339, 1990.
20. Niswender KD, Shiota M, Postic C, Cherrington AD, and Magnuson M. Effects of increased glucokinase gene copy number on glucose homeostasis and hepatic glucose metabolism. J Biol Chem 272: 22570-22575, 1997.
21. Pacini G, Thomaseth K, and Ahrén B. Contribution to glucose intolerance of insulin-independent vs. insulin-dependent mechanisms in mice. Am J Physiol Endocrinol Metab 281: E693-E703, 2001.
22. Pacini G, Tonolo G, Sambataro M, Maioli M, Ciccarese M, Brocco E, Avogaro A, and Nosadini R. Insulin sensitivity and glucose effectiveness: minimal model analysis of regular and insulin-modified FSIGT. Am J Physiol Endocrinol Metab 274: E592-E599, 1998.
23. Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, Shelton KD, Lindner H, Cherrington AD, and Magnuson MA. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic β cell-specific gene knock-outs using cre rcombinase. J Biol Chem 274: 305-315, 1999.
24. Prince MJ, Smith FE, Peters EJ, and Stuart CA. Functional characteristics of decreased insulin receptors on fibroblasts obtained from a subject with severe insulin resistance and acanthosis nigtricans. Diabetes 35: 148-154, 1986.
25. Sörhede Winzell M and Ahrén B. The high-fat diet-fed mouse. A model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53, Suppl 3: S215-S219, 2004.
26. Sörhede Winzell M, Pacini G, Wollheim CB, and Ahrén B. β-Cell targeted expression of a dominant-negative hepatocyte nuclear factor (HNF)-1α in mice: diabetes model with β-cell dysfunction partially rescued by non-glucose secretagogues. Diabetes 53, Suppl 3: S92-S96, 2004.
27. Stumpf JL. Drug therapy of hypertensive crises. Clin Pharmacokinet 7: 582-591, 1988.
28. Tripathy D, Carlsson Å L, Lehto M, Isomaa B, Tuomi T, and Groop L. Insulin secretion and insulin sensitivity in diabetic subgroups: studies in the prediabetic and diabetic state. Diabetologia 43: 1476-1483, 2000.
29. Wang H, Maechler P, Hagenfeldt KA, and Wollheim CB. Dominant-negative suppression of HNF-1α function results in defective insulin gene transcription and impaired metabolism-secretion coupling in a pancreatic β-cell line. EMBO J 17: 6701-6713, 1998.
30. Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H, Vaxillaire M, Southam L, Cox RD, Lahrop GM, Boriraj VV, Chen X, Cox NJ, Oda Y, Yano H, Leeau MM, Yamada S, Nishigori H, Takeda J, Fajans SS, Hattersley AT, Iwasaki N, Hansen T, Pedersen O, Polonsky KS, Rurner RC, Velho G, Chevre JC, Froguel P, and Bell GI. Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young (MODY3). Nature 384: 455-458, 1996.